SCHEMBL4212928

SCHEMBL4212928

Cc1c(Cl)cccc1-c1ccc(C(=O)O)c(Nc2ccc(F)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 7/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
MT-CO2 P00403 1/20 0.47
LMNA P02545 1/20 0.47
TTR P02766 1/20 0.47
PLA2G1B P04054 1/20 0.47
CYP1A2 P05177 1/20 0.47
PGR P06401 1/20 0.47
CYP3A4 P08684 1/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
AR P10275 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
HTR2A P28223 1/20 0.47
CYP2C19 P33261 1/20 0.47
ADRA1A P35348 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227249 0.88 AKR1C3 (0.45) AKR1C3MEN1LMNACYP1A2CYP3A4
SCHEMBL4221487 0.88 PRSS12 (0.50) AKR1C3MEN1TTRKMT2ACLCN2
SCHEMBL4212881 0.83 MCL1 (0.52) AKR1C3MAPTCYP1A2CYP3A4HPGD
SCHEMBL4219566 0.82 CLCN2 (0.48) AKR1C3CLCN2AKR1C2GRIK1DHODH
SCHEMBL4215551 0.81 GRIK1 (0.54) AKR1C3MAPTMEN1USP2LMNA
SCHEMBL4223753 0.81 CLCN2 (0.56) AKR1C3MAPTMEN1USP2CYP1A2
SCHEMBL4213652 0.81 ACMSD (0.55) AKR1C3MAPTMEN1USP2LMNA
SCHEMBL4215681 0.80 GRIK1 (0.54) AKR1C3MEN1USP2KMT2AAKR1C2
SCHEMBL4223743 0.80 CLCN2 (0.48) AKR1C3MEN1USP2LMNATTR
SCHEMBL4213884 0.80 MCL1 (0.56) AKR1C3MAPTAKR1C2DHODHMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 AKR1C3 105/4885MAPT 4791/4885MEN1 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.